Patient Joe Lofaro credits the teamwork of Nishitha Reddy, MBBS, MSCI, and other clinicians at VUMC for diagnosing him with the rare blood cancer Erdheim-Chester disease.
Vanderbilt-Ingram Cancer Center’s Stem Cell Transplant ranks among the best in the nation for donor stem cell transplant survival rates among large centers, according to an annual report.
Vanderbilt’s Pampee Young, MD, PhD, has been named chief medical officer of the American Red Cross.
Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.
Vanderbilt University Medical Center (VUMC) clinicians will host an educational symposium on bone marrow disorders, including bone marrow failure, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), on Friday, Oct. 13, from 11:30 a.m. – 6 p.m. at the Omni Nashville Hotel, 250 5th Ave. South.
Histone deacetylases (HDACs) are enzymes that modulate gene expression and have important roles in development and disease. HDAC inhibitors are active against lymphoma, and understanding the roles of specific HDACs is important for further therapeutic development. Scott Hiebert, Ph.D., and colleagues used a mouse model to explore the role of HDAC3 in the early development […]
For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]
Marco Davila, M.D., Ph.D., assistant professor of Medicine and of Cancer Biology, has received a grant from the Damon Runyon Cancer Research Foundation that will provide $450,000 over three years to help fund his research on therapies for several types of blood disorders, including various forms of leukemia and non-Hodgkin (also known as non-Hodgkin’s) lymphoma. Davila’s […]
Vanderbilt-Ingram Cancer Center (VICC) has entered into a multi-year research support and collaboration agreement with Incyte Corporation. The agreement will support basic and translational research to enable novel therapeutic approaches for patients with cancer. See press release.
Vanderbilt is embarking on an observational study to define and understand how a promising treatment for multiple myeloma affects the heart. The Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT) trial capitalizes on the collaborative relationship between Vanderbilt Heart and Vascular Institute and Vanderbilt-Ingram Cancer Center, with the goal of managing cardiac toxicity […]